Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

afr.com - Michael Smith - Mayne Pharma lands $604m bid from Hungarian drugs group
Mayne Pharma lands $604m bid from Hungarian drugs group
Australian Financial Review –

Hungarian drug maker Gedeon Richter has made a $604 million takeover bid for Mayne Pharma just a week after Mayne announced plans to sell its Adelaide manufacturing plant. Gedeon Richter's offer of $6.40 a share in cash is almost double Mayne's…

afr.com - Mayne Pharma rockets 79pc on takeover bid; Chalmers aims to cut red tape on tax; Gilbert + Tobin private equity partner resigns
Mayne Pharma rockets 79pc on takeover bid; Chalmers aims to cut red tape on tax; Gilbert + Tobin private equity partner resigns
Australian Financial Review –

Want to get this in your inbox at lunchtime every weekday? Financial Review subscribers can sign up for The Brief newsletter here. Plus start your day with our Before the Bell newsletter and read a full wrap of the day's news in Market Wrap. In…

thehindubusinessline.com - BL Mumbai Bureau - DRI search at Cipla involving imported pharma product
DRI search at Cipla involving imported pharma product
The HinduBusinessLine –

Updated - November 17, 2026 at 12:56 PM. | Mumbai Drugmaker Cipla said that the Directorate of Revenue Intelligence (Mumbai zonal unit) had conducted a search at its office in Vikhroli, Mumbai, and at its depot in Bhiwandi, Thane. The search on…

marketbeat.com - Spyglass Pharma (NASDAQ:SGP) Stock Falls 10.1% - What's Next?
Spyglass Pharma (NASDAQ:SGP) Stock Falls 10.1% - What's Next?
MarketBeat –

Shares of Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) traded down 10.1% during trading on Monday. The stock traded as low as $30.00 and last traded at $29.5510. 32,138 shares traded hands during trading, a decline of 70% from the average…

marketbeat.com - Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
Urogen Pharma (NASDAQ:URGN) Shares Gap Down - What's Next?
MarketBeat –

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares trading…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Stock Gets Price Target Trim from Morgan Stanley
Avalyn Pharma (NASDAQ:AVLN) Stock Gets Price Target Trim from Morgan Stanley
MarketBeat –

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) had its price target dropped by equities researchers at Morgan Stanley from $57.00 to $53.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an…

marketbeat.com - Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Barclays Analyst Says
Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Barclays Analyst Says
MarketBeat –

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by stock analysts at Barclays from $329.00 to $341.00 in a research note issued to investors on Monday, Benzinga reports. The firm presently has an 'overweight' rating…

the-decoder.com - Manuel Uth - Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
Moonshot AI pivots Kimi models from coding to science as benchmark gains flatten
The Decoder –

Because Moonshot AI sees diminishing returns in coding, the Beijing startup is redirecting its Kimi language models toward biology, chemistry, and pharma research. International director Giacomo Ficari said at the Web Summit in Lisbon that science…

statnews.com - Andrew Joseph - FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
FDA approves new breast cancer drug, providing new option for some patients, boost for Roche
STAT –

The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever. The approval of Wilserdly, also known as…

cnbc.com - Natasha Abellard - Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
CNBC –

Johnson & Johnson is a prime example of the kind of stock doing well in the broader market as investors shy away from the volatile artificial intelligence trade. '[J & J] is a metaphor for what's working,' Jim Cramer said Monday on CNBC, as shares…

statnews.com - Margaret Manto - In a win for MAHA, FDA creates new regulatory category for the supplement NAC
In a win for MAHA, FDA creates new regulatory category for the supplement NAC
STAT –

WASHINGTON – The Food and Drug Administration is proposing a new classification for a product that's existed in a legal grey area for years, a win for proponents of dietary supplements, including members of the MAHA movement. The proposed…

swissinfo.ch - Jessica Davis Plüss - Swiss patients face unequal access to life-saving treatment
Swiss patients face unequal access to life-saving treatment
www.swissinfo.ch –

After a long legal battle with the Federal Office of Public Health (FOPH), RTS obtained data behind a 2020 government-commissioned report that showed huge disparities in insurance coverage of new treatments. The investigationExternal link by RTS…

bbc.co.uk - Ben Carr - Guilt continues' for families harmed by sodium valproate scandal
Guilt continues' for families harmed by sodium valproate scandal
BBC –

'Even though I know it's not my fault, the guilt continues and I don't think it will ever go away.' Emma Friedmann's son Andrew is one of an estimated 20,000 children in UK believed to have been harmed by the epilepsy drug sodium valproate since it…

seekingalpha.com - Albert Anthony - Gladstone Land: Q3 Growth Spurt, But Caution Remains Over Farmland Earnings Volatility (Rating Downgrade)
Gladstone Land: Q3 Growth Spurt, But Caution Remains Over Farmland Earnings Volatility (Rating Downgrade)
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…

seekingalpha.com - Albert Anthony - FrontView REIT: Diverse Retail Portfolio Shows Durability After Q3 Growth And Earnings Performance
FrontView REIT: Diverse Retail Portfolio Shows Durability After Q3 Growth And Earnings Performance
Seeking Alpha –

Albert Anthony is the pen name of a business author on Amazon and a contributing analyst to investing platforms like Seeking Alpha since 2023, where he has over + 2,000 followers and has covered hundreds of stocks in multiple sectors including…

Receive a Daily briefing on Pharma Industry News

Get Started